Latest News and Press Releases

MENLO PARK, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...

- FDA decision on New Drug Application expected by June 30, 2018 - Licensed exclusive, worldwide rights to lebrikizumab from Roche - Completed patient enrollment in two Phase 3 trials for the...

Dermira to transition development and commercialization responsibility for CIMZIA® (certolizumab pegol) in psoriasis back to UCBDecision reflects both companies’ strategic prioritiesUCB remains...

- Daily treatment with glycopyrronium tosylate in the Phase 3, open-label ARIDO trial was generally well-tolerated during 44 weeks of treatment- Efficacy assessment suggests sweat reduction levels...

- Phase 3 pivotal trials enrolled a total of 1,503 patients- Topline efficacy and safety results expected in first quarter of 2018 MENLO PARK, Calif., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Dermira,...

MENLO PARK, Calif., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...

MENLO PARK, Calif., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...

Presentations included the first 48-week data from the CIMPASI-1 and CIMPASI-2 psoriasis trials, and re-randomized data through 48 weeks from the CIMPACT psoriasis trial 1,2Treatment with CIMZIA was...

People suffering from primary axillary hyperhidrosis (excessive underarm sweating beyond what is needed to maintain normal body temperature) report that the condition has a significant impact on their...

New findings from the glycopyrronium tosylate Phase 3 program highlight potential benefits of the investigational treatment and the impact of primary axillary hyperhidrosis on patients’ daily...